University of Massachusetts Medical School
Welcome,         Profile    Billing    Logout  
 18 Trials 
32 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rothschild, Anthony
NCT05624268: Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD

Recruiting
3
255
US
Psilocybin, COMP360
COMPASS Pathways
Treatment Resistant Depression
02/25
02/26
Nadjafi, Morteza
NCT05624268: Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD

Recruiting
3
255
US
Psilocybin, COMP360
COMPASS Pathways
Treatment Resistant Depression
02/25
02/26
EBS-101-TD-391, NCT06021522: A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette's Disorder

Recruiting
3
150
Europe, Canada, US, RoW
Ecopipam, Ecopipam Hydrochloride
Emalex Biosciences Inc.
Tourette Syndrome
11/24
03/27
D1AMOND, NCT05615220: Ecopipam Tablets to Study Tourette's Disorder in Children, Adolescents and Adults

Active, not recruiting
3
196
Europe, Canada, US, RoW
Ecopipam Hydrochloride
Emalex Biosciences Inc.
Tourette Disorder
12/24
12/24
NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Recruiting
3
568
Europe, Canada, US, RoW
Psilocybin, COMP360
COMPASS Pathways
Treatment Resistant Depression
03/25
05/25
NCT05081245: ML-004 in Adolescents and Adults with Autism Spectrum Disorders (ASD)

Recruiting
2
150
Canada, US, RoW
ML-004 (IR)/(ER) tablet, ML-004 Placebo
MapLight Therapeutics
Autism Spectrum Disorder
03/25
04/25
UNCOVER, NCT04753385: The RECOVER sUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes

Terminated
N/A
138
US
LivaNova
Treatment Resistant Depression
09/24
09/24
RECOVER, NCT03887715: A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression

Recruiting
N/A
6800
US
Vagus Nerve Stimulation (VNS), VNS
LivaNova
Treatment Resistant Depression
02/28
12/30
DeBattista, Charles
NCT04249596: Tianeptine for Treatment Resistant Depression

Recruiting
4
75
US
Tianeptine Sodium, Tianeurex 12.5 mg
New York State Psychiatric Institute, Icahn School of Medicine at Mount Sinai, Stanford University
Treatment Resistant Depression
12/25
12/25
NCT05624268: Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD

Recruiting
3
255
US
Psilocybin, COMP360
COMPASS Pathways
Treatment Resistant Depression
02/25
02/26
Bodkin, Noelle
PICASSO, NCT05611242: Proximal Internal Carotid Artery Acute Stroke Secondary to Tandem or Local Occlusion Thrombectomy Trial

Recruiting
3
404
US
MT+CAS with IV-AP, Thrombectomy, MT+CAS with PO-AP, MT+CAT with PO-AP
Mercy Health Ohio
Acute Ischemic Stroke
03/26
05/27
ENDOLOW, NCT04167527: Endovascular Therapy for Low NIHSS Ischemic Strokes

Recruiting
2/3
200
Europe, Canada, US
Immediate mechanical thrombectomy(iMT) using EmboTrap Revascularization Device, EmboTrap III, Initial medical management (iMM)
Emory University, University of Calgary, University of Cincinnati, Heidelberg University, Children's Hospital Medical Center, Cincinnati
Cerebral Ischemia
12/24
12/24
NCT05018650: A Randomized, Controlled Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical Reperfusion System (SUMMIT MAX)

Active, not recruiting
N/A
250
US, RoW
Route 92 Medical Reperfusion System
Route 92 Medical, Inc.
Acute Ischemic Stroke
06/24
06/24
WEB PAS, NCT04839705: Post Approval Study - Evaluate the Long-Term Safety and Effectiveness of the WEB Device

Recruiting
N/A
180
US
WEB
Microvention-Terumo, Inc.
Wide Neck Bifurcation Intracranial Aneurysms
12/25
12/29
CREST-2, NCT02089217: Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial

Active, not recruiting
N/A
2486
Europe, Canada, US, RoW
Carotid endarterectomy (CEA), Carotid Stenting (CAS), Intensive Medical Management - no CEA, Intensive Medical Management - no CAS
Thomas G. Brott, M.D., National Institute of Neurological Disorders and Stroke (NINDS)
Carotid Stenosis
02/26
02/26
NCT04057352: Citadel Embolization Device Study

Recruiting
N/A
150
US
Citadel Embolization Device
Stryker Neurovascular
Unruptured Wide-neck Aneurysms
06/26
06/26
Duell, Jayna
HEALEY ALS, NCT04297683: Platform Trial - Master Protocol

Active, not recruiting
2/3
1500
US
ABBV-CLS-7262, DNL343
Merit E. Cudkowicz, MD, Massachusetts General Hospital
Amyotrophic Lateral Sclerosis
07/25
04/26
Duthie, Beverley
HEALEY ALS, NCT04297683: Platform Trial - Master Protocol

Active, not recruiting
2/3
1500
US
ABBV-CLS-7262, DNL343
Merit E. Cudkowicz, MD, Massachusetts General Hospital
Amyotrophic Lateral Sclerosis
07/25
04/26
CNMAu8.EAP02, NCT05281484: Two Intermediate Expanded Access Protocols (EAP) CNMAu8.EAP01 and for ALS

Available
N/A
US
CNM-Au8, Nanocrystalline gold
Clene Nanomedicine
Amyotrophic Lateral Sclerosis
 
 
Douthwright, Catherine
HEALEY ALS, NCT04297683: Platform Trial - Master Protocol

Active, not recruiting
2/3
1500
US
ABBV-CLS-7262, DNL343
Merit E. Cudkowicz, MD, Massachusetts General Hospital
Amyotrophic Lateral Sclerosis
07/25
04/26
Suplicy, Felipe
KP415P02, NCT05721235: A Safety/Tolerability and PK Study With Azstarys® in Children With ADHD

Active, not recruiting
4
123
US
Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)
Corium, Inc., Premier Research Group plc, Prometrika, LLC, Almac, Worldwide Clinical Trials
Attention Deficit/Hyperactivity Disorder
07/25
07/25
NCT06389487: A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus (RSV) Given to Adults 18 to 49 Years of Age at Increased Risk for Respiratory Syncytial Virus Disease, Compared to Older Adults 60 Years of Age and Above

Active, not recruiting
3
1457
Europe, Canada, Japan, US, RoW
RSVPreF3 OA investigational vaccine
GlaxoSmithKline
Respiratory Syncytial Virus Infections
07/24
04/25
NCT05624268: Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD

Recruiting
3
255
US
Psilocybin, COMP360
COMPASS Pathways
Treatment Resistant Depression
02/25
02/26
NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Recruiting
3
568
Europe, Canada, US, RoW
Psilocybin, COMP360
COMPASS Pathways
Treatment Resistant Depression
03/25
05/25
REPOSA, NCT06146101: RePOSA-Revealing the Efficacy of IHL-42X Use in Patients with OSA

Recruiting
2/3
560
US
IHL-42X Low Dose, Phase 2 Investigational Product - IHL-42X Low dose, IHL-42X High Dose, Phase 2 Investigational Product - IHL-42X High dose, Placebo, Phase 2 Placebo, IHL-42X (Optimal Dose), Phase 3 Investigational Product - IHL-42X, Dronabinol, Phase 3 Comparator - Reference Listed Drug/Dronabinol, Acetazolamide, Phase 3 Comparator - Reference Listed Drug/Acetazolamide, Phase 3 Placebo
Incannex Healthcare Ltd
Obstructive Sleep Apnea
12/26
12/26
NCT06702449: A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age

Recruiting
1/2
448
Europe, US, RoW
Candidate UTI vaccine low dose formulation 1, Candidate UTI vaccine low dose formulation 2, Candidate UTI vaccine medium dose formulation 1, Candidate UTI vaccine medium dose formulation 2, Candidate UTI vaccine high dose formulation 1, Candidate UTI vaccine high dose formulation 2, Candidate UTI vaccine HTD formulation 2, Placebo
GlaxoSmithKline
Urinary Tract Infections
08/27
08/27
Kitwood, Schiara
NCT05624268: Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD

Recruiting
3
255
US
Psilocybin, COMP360
COMPASS Pathways
Treatment Resistant Depression
02/25
02/26
Sublok, Mandeep
NCT05624268: Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD

Recruiting
3
255
US
Psilocybin, COMP360
COMPASS Pathways
Treatment Resistant Depression
02/25
02/26
Reyes, Arjun
NCT05624268: Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD

Recruiting
3
255
US
Psilocybin, COMP360
COMPASS Pathways
Treatment Resistant Depression
02/25
02/26
Vilchinsky, Lauren
NCT05624268: Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD

Recruiting
3
255
US
Psilocybin, COMP360
COMPASS Pathways
Treatment Resistant Depression
02/25
02/26
NCT06419608: Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression

Recruiting
2
300
US
BHV-7000, Placebo
Biohaven Therapeutics Ltd.
Major Depressive Disorder
05/25
07/25
Okasha, Sharif
NCT05624268: Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD

Recruiting
3
255
US
Psilocybin, COMP360
COMPASS Pathways
Treatment Resistant Depression
02/25
02/26

Download Options